

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

comparison between herbal medicine myrrh , sesamum indicum and oral contraceptive pills for treatment of incomplete abortion

Protocol summary

Study aim

comparison between herbal medicine myrrh , sesamum indicum and oral contraceptive pills for treatment of incomplete abortion

Design

This clinical trial study has a control group, including 4 groups, including group A, LD which is a type of OCP pill, group B, Myrrhs capsule, group C, dried sesame extract capsule and the control group receiving capsules with Avicel. Treatment in groups is done in parallel. 160 patients will be randomly divided into 4 groups. The study was conducted in a double-blind manner, and the patients and the examiner of the results will not be aware of the type of drug used.

Settings and conduct

In this study, 160 patients referred to teaching and therapeutic hospitals affiliated to Shiraz University of Medical Sciences were randomly divided into four groups: group A, LD which is a type of OCP pill, group B, Myrrhs capsules, group C, capsules of dried sesame extract and group Control recipients will be divided into capsules with Avicel. In each group, all medicines will be designed in the same way and the patient will take the medicine for 14 days. The doctors and the examiner of the result will not be aware of the type of drug used. After the end of the transvaginal color Doppler ultrasound treatment, the remnants of the placenta after the abortion are examined and measured by a radiologist.

Participants/Inclusion and exclusion criteria

healthy women with a normal blood count (hemoglobin > 9) , estimated gestational age less than 20 weeks, with intrauterine tissue with an anterior posterior diameter 15-50 mm less than 1month post abortion, BMI ≤ 30

Intervention groups

Group A (n=40), LD capsule combined with Avasil Group B (n=40), Myrrhs capsule 500 mg BID Group C (n=40), capsules of dried sesame extract Group D 40 (n=40) placebo capsules (containing Avacil). In all groups,

medicine (capsule) is prescribed for 14 days

Main outcome variables

incomplete abortion

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20240109060656N1**

Registration date: **2024-02-08, 1402/11/19**

Registration timing: **registered_while_recruiting**

Last update: **2024-02-08, 1402/11/19**

Update count: **0**

Registration date

2024-02-08, 1402/11/19

Registrant information

Name

Mojtaba Neydavoodi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3230 5410

Email address

neydavodi41@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-01-21, 1402/11/01

Expected recruitment end date

2024-03-19, 1402/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
comparison between herbal medicine myrrh , sesamum indicum and oral contraceptive pills for treatment of incomplete abortion

Public title
herbal medicine myrrh , sesamum indicum and oral contraceptive pill for treatment of incomplete abortion

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
healthy women with a normal blood count (hemoglobin > 9) estimated gestational age less than 20 weeks with intrauterine tissue with an anterior posterior diameter 10-15 mm less than 1 month post abortion BMI ≤ 30 no fever no pelvic tenderness no infection in vaginal exam Age between 18 and 35 years
Exclusion criteria:
Age less than 18 and more than 35 years BMI>30 Presence of infection in vaginal examination

Age
From **18 years** old to **35 years** old

Gender
Female

Phase
1-2

Groups that have been masked

- Participant
- Outcome assessor

Sample size
Target sample size: **160**

Randomization (investigator's opinion)
Randomized

Randomization description
This study includes 160 patients in 4 groups. 160 patients were divided into 40 blocks of 4. Each block is numbered and will be used for 4 patients, that is, if block number 2 is selected in the lottery, the first patient will receive treatment A, the second patient will receive treatment B, the third patient will receive treatment C, and the fourth patient will receive treatment D. The fifth patient will be randomly selected from one of the blocks and the type of treatment will be assigned to the fifth to eighth patients according to the block.

Blinding (investigator's opinion)
Double blinded

Blinding description
The study was conducted in a double-blind manner, and the patients and the examiner of the results (our expert radiologist) will not be aware of the type of drug used. Each drug is placed in a box in the package with a corresponding number label so that the patient does not have any information about the type of drug used. The shape and packaging of myrrh and OCP capsules and sesame and placebo are similar. In this study, our nurse colleague in the hospital affiliated to Shiraz University of

Medical Sciences will deliver medicine and placebo to the study participants based on the random block table.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Shiraz University of Medical Sciences

Street address

Zand Street, in front of Palestine Street, central building of Shiraz University of Medical Sciences

City

Shiraz

Province

Fars

Postal code

7134814336

Approval date

2023-12-24, 1402/10/03

Ethics committee reference number

IR.SUMS.MED.REC.1402.429

Health conditions studied

1

Description of health condition studied

incomplete abortion

ICD-10 code

O03. 4

ICD-10 code description

Spontaneous abortion Incomplete, without complication.

Primary outcomes

1

Description

Remaining remnants of the placenta after abortion

Timepoint

After the end of 14 days of treatment

Method of measurement

Using the findings observed in transvaginal color doppler ultrasound

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: In group A, LD, which is a type of OCP tablet that is placed inside the capsule with Avacil and is prepared as a capsule. This capsule is prescribed for 40 patients for 14 days

Category

Treatment - Drugs

2

Description

Intervention group: Group B Myrrhs capsules to 40 patients, 500 mg BID for 14 days

Category

Treatment - Drugs

3

Description

Intervention group: Group C (n=40), Contact capsules with dried sesame extract are given to 40 patients for 14 days (BID).

Category

Treatment - Drugs

4

Description

40 patients will receive a placebo capsule (containing Avacil) for 14 days.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Medical educational hospitals affiliated to Shiraz University of Medical Sciences

Full name of responsible person

Fatemeh Rowshani

Street address

Zand Street, in front of Palestine Street, central building of Shiraz University of Medical Sciences

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Email

f.rowshani@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Mohammad Hashem Hashempour

Street address

Zand Street, in front of Palestine Street, central building of Shiraz University of Medical Sciences

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3235 7282

Email

hashempurm@sums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Fatemeh Rowshani

Position

Obstetrics and Gynecology assistant student

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Zand Street, in front of Palestine Street, central building of Shiraz University of Medical Sciences

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Email

f.rowshani@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Fatemeh Rowshani

Position

Obstetrics and Gynecology assistant student

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Zand Street, in front of Palestine Street, central building of Shiraz University of Medical Sciences

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Email

f.rowshani@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Fatemeh Rowshani

Position

Obstetrics and Gynecology assistant student

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Zand Street, in front of Palestine Street, central building of Shiraz University of Medical Sciences

City

shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Email

f.rowshani@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

Data related to the study will not be published

When the data will become available and for how long

Data related to the study will not be published

To whom data/document is available

Data related to the study will not be published

Under which criteria data/document could be used

Data related to the study will not be published

From where data/document is obtainable

Data related to the study will not be published

What processes are involved for a request to access data/document

Data related to the study will not be published

Comments